Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 375 participants.

Also called NCT01059825

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 375 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01059825
  • EudraCT 2009-017131-18
Other papers using this trial's data
  • Dose-ranging efficacy and safety study of ertugliflozin, a sodium-glucose co-transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin Diabetes, obesity & metabolism, 2015-06 DOI, PubMed 25754396

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01059825. Randomized; double masking; primary purpose treatment. Start 2010-02-24 (actual); primary completion 2011-01-20 (actual). Results posted on 2017-10-04.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Placebo to Ertugliflozin
Intervention (Drug)
Ertugliflozin 1 mg
Intervention (Drug)
Ertugliflozin 5 mg
Intervention (Drug)
Ertugliflozin 25 mg
Intervention (Drug)
Sitagliptin 100 mg
Intervention (Drug)
Placebo to Sitagliptin
Intervention (Drug)
Metformin
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)
Collaborator
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct01059825
Content hash
ffd4a1afc7a5f1f5c1071c64220985652f91c8356564c07c10e130e2cf41a35a